Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
SERA filed a Rule 144 notice for Class A Common shares tied to a Restricted Stock Unit vesting of 3,119 shares on 03/09/2026. The broker listed is Morgan Stanley Smith Barney LLC. The filing also records a prior reported sale by Benjamin Jackson of 892 shares on 12/10/2025.
SERA reports a Form 144 notice of proposed sale of Class A Common shares. The filing lists 03/09/2026 as the date securities to be sold (restricted stock units vesting) and records prior open-market dispositions of Class A Common on 12/10/2025, 12/30/2025, 01/27/2026, and 02/24/2026 with per-sale share counts of 616, 2000, 2000, and 2000, respectively.
The filing identifies Morgan Stanley Smith Barney LLC and lists Robert Harrison as a reporting address associated with prior sales. The notice indicates the shares to be sold arise from restricted stock unit vesting on 03/09/2026.
SERA filed a Form 144 reporting Restricted Stock Unit vesting for Class A Common stock on 03/09/2026. The filing also records a prior resale of 1,332 shares on 12/10/2025. The notice lists numbers tied to the securities and intermediary details.
SERA notice of proposed sale of Class A Common shares tied to Restricted Stock Unit vesting.
The filing lists securities to be sold on 03/09/2026 arising from Restricted Stock Unit vesting. It also reports prior sales by Austin Aerts: 12/09/2025 (5,232 shares) and 12/10/2025 (873 shares) as shown in the table.
SERA PROGNOSTICS, INC. director Sandra AJ Lawrence reported an open-market sale of 1,560 shares of Class A common stock at a weighted average price of $1.95 per share. The sale was made under a Rule 10b5-1 trading plan adopted on June 10, 2025. After this transaction, she directly holds 18,033 shares.
SERA filed a Form 144 reporting a proposed sale of 1,560 shares of common stock.
The filing identifies the securities as Restricted Stock Units dated 01/05/2026 and records prior 10b5-1 sales by Sandra A J Lawrence of 1,560 shares on 12/08/2025. The notice lists NASDAQ as the market and 03/06/2026 appears as a filing reference date.
SERA PROGNOSTICS, INC. Chief Information Officer Harrison Robert Gardner reported an open-market sale of 2,000 shares of Class A Common Stock. The shares were sold at a weighted average price of $2.34 per share, in transactions ranging from $2.23 to $2.45. After this sale, Gardner directly holds 80,788 shares of Sera Prognostics common stock. The transaction was carried out under a pre-established Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2025, which is designed to systematically execute trades according to preset instructions.
Robert Harrison filed a Form 144 reporting a proposed sale of 2,000 Common shares (listed as Restricted Stock Units) through Morgan Stanley Smith Barney LLC. The filing also lists recent 10b5-1 sales: 2,000 shares on 01/27/2026, 2,000 on 12/30/2025, 616 on 12/10/2025, and 2,000 on 12/02/2025.
Sera Prognostics, Inc. director Kim P. Kamdar reported a restructuring of her holdings through a pro rata distribution by Domain Associates, LLC. Domain Associates distributed 30,920 shares of Class A common stock it held for her indirect benefit, for no consideration, reducing her indirect holdings to zero. As part of the same distribution, Kamdar received 3,231 shares of Class A common stock directly, also for no consideration, bringing her directly held stake to 32,573 shares. The transactions are coded as “J,” reflecting the internal reallocation and not a market purchase or sale.
Sera Prognostics, Inc. insider Harrison Robert Gardner, the company’s Chief Information Officer, reported selling 2,000 shares of Class A common stock on January 27, 2026 at a reported price of $2.97 per share. After this transaction, he beneficially owned 82,788 shares directly.
The sale was carried out under a pre-established Rule 10b5-1 trading plan that Gardner adopted on May 21, 2025. The filing notes the reported price is a weighted average, with individual trades executed between $2.92 and $3.06 per share.